Literature DB >> 1533349

Platelet-dependent thrombin generation after in vitro fibrinolytic treatment.

D L Aronson1, P Chang, C M Kessler.   

Abstract

BACKGROUND: Fibrinolytic therapy is associated with frequent rethrombosis. There is evidence of both increased coagulation and platelet activation. METHODS AND
RESULTS: Platelet-rich plasma (PRP) or washed platelets were incubated with the fibrinolytic agents urokinase, recombinant tissue-type plasminogen activator (rt-PA), or plasmin at concentrations consistent with those in the plasma of patients treated for myocardial infarction. All of the fibrinolytic agents induced a more rapid generation of thrombin and decreased the clotting times of non-contact-activated PRP than in untreated PRP. This effect was not blocked by the inclusion of thrombin inhibitors during the fibrinolytic treatment. Washed platelets derived from rt-PA-treated PRP induced more rapid thrombin generation when resuspended in untreated plasma or treated plasma. Washed platelets were treated with plasmin, rt-PA, and urokinase and added to platelet-poor plasma. Platelets treated with either plasmin or rt-PA increased the ability of washed platelets to support thrombin generation, but urokinase was without significant effect.
CONCLUSIONS: These results indicate not only that plasmin can cause increased platelet support of prothrombin activation but also that rt-PA in the absence of plasminogen can have a direct effect on the platelet, which increases thrombin generation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533349     DOI: 10.1161/01.cir.85.5.1706

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction.

Authors:  N S Kleiman; R P Tracy; J D Talley; K Sigmon; D Joseph; E J Topol; R M Califf; M Kitt; E M Ohman
Journal:  J Thromb Thrombolysis       Date:  2000-01       Impact factor: 2.300

Review 3.  Antifibrinolytic Therapy and Perioperative Considerations.

Authors:  Jerrold H Levy; Andreas Koster; Quintin J Quinones; Truman J Milling; Nigel S Key
Journal:  Anesthesiology       Date:  2018-03       Impact factor: 7.892

4.  Effect of nano-scale curvature on the intrinsic blood coagulation system.

Authors:  Takashi Kushida; Krishnendu Saha; Chandramouleeswaran Subramani; Vikas Nandwana; Vincent M Rotello
Journal:  Nanoscale       Date:  2014-11-06       Impact factor: 7.790

5.  Correlation between clinical course and quantitative analysis of the ischemia related artery in patients with unstable angina pectoris, refractory to medical treatment. Results of two randomized trials. The European Cooperative Study Group.

Authors:  M J van den Brand; A van Miltenburg; M J de Boer; L R van der Wieken; P J de Feyter; M L Simoons
Journal:  Int J Card Imaging       Date:  1994-09

Review 6.  Drug interactions with thrombolytic agents. Current perspectives.

Authors:  A de Boer; J M van Griensven
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 7.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 8.  Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.

Authors:  J C Gillis; A J Wagstaff; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 9.  Assessing Plasmin Generation in Health and Disease.

Authors:  Adam Miszta; Dana Huskens; Demy Donkervoort; Molly J M Roberts; Alisa S Wolberg; Bas de Laat
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.